natgillin/translations-raw huggingface dataset:
All of the patients received Orencia for four months, before the 122 who responded were then either switched to placebo or continued receiving Orencia.
Vsi bolniki so zdravilo Orencia prejemali štiri mesece, nato pa je 122 bolnikov, ki so se odzvali na zdravljenje, prešlo na jemanje placeba ali pa so še naprej prejemali zdravilo Orencia.
All of the patients were also receiving G-CSF.
Vsi bolniki so prejemali tudi G-CSF.
All of the patients were over 50 years of age and had not been treated for wet AMD before.
Vsi bolniki so bili starejši od 50 let in se pred tem še niso zdravili zaradi vlažne oblike te bolezni.
All of the patients were treated with at least one regimen prior to enrolment into the study, 16.0% with one prior regimen, and 84% with two or more regimens.
Vsi bolniki so pred vključitvijo v študijo že prejemali zdravila po najmanj enem režimu; 16,0 % bolnikov se je predhodno zdravilo po enem režimu in 84 % bolnikov po dveh ali več režimih.
All of the studies assessed the patients’ responses by measuring the levels of white cells and platelets in the blood, to see if they were returning to normal, and by measuring the number of white blood cells that contained the Philadelphia chromosome, to see if it was decreasing.
V vseh študijah so odziv bolnikov ocenjevali z merjenjem količine belih krvnih celic in trombocitov v krvi, da bi ugotovili, ali so se te vrnile na normalne ravni, in merjenjem deleža belih krvnih celic, ki vsebujejo kromosom Philadelphia, da bi ugotovili, ali se je ta znižal.
All of the studies compared Tasmar with placebo (a dummy treatment) when they were added to the patient’s existing medication (levodopa and either carbidopa or benserazide).
V vseh študijah so zdravilo Tasmar primerjali s placebom (zdravilom brez zdravilne učinkovine), ki so ju dodajali zdravilom, ki jih je bolnik že jemal (levodopi in bodisi karbidopi ali benserazidu).
All of the studies lasted for a year (13 four-week cycles).
Vse študije so trajale eno leto (13 štiritedenskih ciklusov).
All of the studies looked at the ability of the vaccine to trigger the production of antibodies (‘immunogenicity’) against H5N1.
V vseh študijah so proučevali sposobnost cepiva, da sproži nastajanje protiteles („imunogenost“) proti virusu H5N1.
All of the studies measured the change in the patient’s symptoms using a standard scale for schizophrenia.
V vseh študijah so merili spremembo bolnikovih simptomov na podlagi standardne ocenjevalne lestvice za shizofrenijo.
All of the studies measured the level of ‘fasting’ blood glucose (measured when the patient had not eaten for at least eight hours) or a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well blood glucose is controlled.
V vseh študijah so merili raven glukoze v krvi na tešče (izmerjene vsaj osem ur po zadnjem obroku) ali snovi v krvi, imenovane glikozilirani hemoglobin (HbA1c), ki kaže, kako učinkovito je raven glukoze v krvi nadzorovana.
All of the studies measured the level of ‘fasting’ blood glucose (measured when the patients had not eaten for at least eight hours) or a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well blood glucose is controlled.
V vseh študijah so merili raven glukoze v krvi na tešče (izmerjene vsaj osem ur po zadnjem obroku) ali snovi v krvi, imenovane glikozilirani hemoglobin (HbA1c), ki kaže, kako učinkovito je raven glukoze v krvi nadzorovana.
All of the studies showed that combinations including Stocrin were at least as effective as the comparator medicines: the first study showed that 67% of the adults treated with Stocrin in combination with zidovudine and lamivudine had viral loads below 400 copies/ml after 48 weeks, compared with 54% of the patients treated with Stocrin and indinavir, and 45% of the patients treated with indinavir, lamivudine and zidovudine; in the second study, Stocrin in combination with nelfinavir was superior to the combination without Stocrin: 70% and 30% of the patients, respectively, had viral loads below 500 copies/ml after 48 weeks; the third study showed that more patients receiving Stocrin had viral loads below 400 copies/ml than those taking placebo after 24 weeks.
Vse študije so pokazale, da so bile kombinacije, ki so vključevale zdravilo Stocrin, vsaj tako učinkovite kot primerjalna zdravila: prva študija je pokazala, da je imelo 67 % odraslih, zdravljenih z zdravilom Stocrin v kombinaciji z zidovudinom in lamivudinom, po 48 tednih virusno breme pod 400 kopij/ml v primerjavi s 54 % bolnikov, zdravljenih z zdravilom Stocrin in indinavirom, ter 45 % bolnikov, zdravljenih z indinavirom, lamivudinom in zidovudinom; v drugi študiji je bilo zdravilo Stocrin v kombinaciji z nelfinavirom učinkovitejše od kombinacije brez zdravila Stocrin: 70 % oziroma 30 % bolnikov je imelo po 48 tednih virusno breme pod 500 kopij/ml; tretja študija je pokazala, da je imelo po 24 tednih več bolnikov, ki so prejemali zdravilo Stocrin, virusno breme pod 400 kopij/ml kot tistih, ki so prejemali placebo.
All of the studies showed that combinations including Sustiva were at least as effective as the comparator medicines: the first study showed that 67% of the adults treated with Sustiva in combination with zidovudine and lamivudine had viral loads below 400 copies/ml after 48 weeks, compared with 54% of the patients treated with Sustiva and indinavir, and 45% of the patients treated with indinavir, lamivudine and zidovudine; in the second study, Sustiva in combination with nelfinavir was superior to the combination without Sustiva: 70% and 30% of the patients, respectively, had viral loads below 500 copies/ml after 48 weeks; the third study showed that more patients receiving Sustiva had viral loads below 400 copies/ml than those taking placebo after 24 weeks.
Vse študije so pokazale, da so bile kombinacije, ki so vključevale zdravilo Sustiva, vsaj tako učinkovite kot primerjalna zdravila: prva študija je pokazala, da je imelo 67 % odraslih, zdravljenih z zdravilom Sustiva v kombinaciji z zidovudinom in lamivudinom, po 48 tednih virusno breme pod 400 kopij/ml v primerjavi s 54 % bolnikov, zdravljenih z zdravilom Sustiva in indinavirjem, ter 45 % bolnikov, zdravljenih z indinavirjem, lamivudinom in zidovudinom; v drugi študiji je bilo zdravilo Sustiva v kombinaciji z nelfinavirjem učinkovitejše od kombinacije brez zdravila Sustiva: 70 % oziroma 30 % bolnikov je imelo po 48 tednih virusno breme pod 500 kopij/ml; tretja študija je pokazala, da je imelo po 24 tednih več bolnikov, ki so prejemali zdravilo Sustiva, virusno breme pod 400 kopij/ml kot tistih, ki so prejemali placebo.
All of the tablets must be taken together at the same time every day, at least one hour before or one hour after food.
Vse tablete je treba vzeti sočasno vsak dan ob istem času, najmanj eno uro pred obrokom ali eno uro po njem.
All of these also resolved, 2 with continuation of both medicinal products and 3 after discontinuation of leflunomide.
Tudi pri teh je izginilo, pri ob nadaljevanju uporabe obeh zdravil in pri 3 po opustitvi leflunomida.
All of these bivalirudin- treated patients received concomitant acetylsalicylic acid, all but 1 received clopidogrel and 15 also received a GP IIb/IIIa inhibitor.
Vsi bolniki, ki so se zdravili z bivalirudinom, so prejeli hkrati acetisalicilno kislino, vsi razen 1 so prejeli klopidogrel, 15 pa jih je prejelo tudi zaviralec GP IIb/IIIa.
All of these effects are reversible.
Vsi opisani učinki so reverzibilni..
All of these events were Grade 1/2 and were confounded by multiple factors.
Vsi ti dogodki so bili stopnje 1/2 in so nanje vplivali še številni drugi dejavniki.
All of these pathways involve the biodegradation of the antibody to smaller molecules, i.e. small peptides or amino acids.
V vseh teh poteh pride do biološke razgradnje protiteles na manjše molekule, t.j. majhne peptide ali aminokisline.
All of these patients had risk factors for fainting.
Pri vseh teh bolnikih je obstajalo tveganje za omedlevico.
All of these reactions resolved with treatment discontinuation.
Vsi omenjeni učinki so izginili po ukinitvi zdravljenja.
All of these studies lasted 48 weeks, and compared the effectiveness of Pegasys with that of interferon alfa-2a.
Vse te študije so trajale 48 tednov, v njih pa so primerjali učinkovitost zdravila Pegasys z učinkovitostjo interferona alfa-2a.
All of these studies looked at the change in symptoms using a standard scale for bipolar disorder or at the number of patients who responded to treatment.
V vseh teh študijah so proučevali spremembo simptomov na podlagi standardne ocenjevalne lestvice za bipolarno motnjo ali beležili število bolnikov, ki so se odzvali na zdravljenje.
All of zaleplon’s metabolites are inactive in both animal behavioural models and in vitro activity assays.
Vsi presnovki zaleplona so neaktivni tako v živalskih vedenjskih modelih kot pri in vitro določanju aktivnosti.
All olanzapine- and placebo-treated patients who experienced a cerebrovascular event had pre- existing risk factors.
Vsi bolniki, ki so prejemali olanzapin ali placebo in so doživeli cerebrovaskularni dogodek, so imeli prej obstoječe dejavnike tveganja.
All other causes of anaemia (iron deficiency, haemolysis, blood loss, vitamin B12- or folate deficiencies) should be considered and treated prior to initiating and during therapy with Retacrit.
Vse druge vzroke anemije (pomanjkanje železa, hemoliza, izguba krvi, pomanjkanje folne kisline ali vitamina B12) je treba izključiti oziroma zdraviti pred začetkom zdravljenja in med zdravljenjem z zdravilom Retacrit.
All other causes of anaemia (iron, folate or vitamin B12 deficiency, aluminium intoxication, infection or inflammation, blood loss, haemolysis and bone marrow fibrosis of any origin) should be evaluated and treated prior to initiating therapy with epoetin alfa, and when deciding to increase the dose.
Pred začetkom zdravljenja z epoetinom alfa in pri odločitvi za povečanje odmerka je treba oceniti in zdraviti vse druge vzroke anemije (pomanjkanje železa, folata ali vitamina B12, zastrupitev z aluminijem, okužba ali vnetje, izguba krvi, hemoliza ali fibroza kostnega mozga katerega koli izvora).
All other infections (viral, bacterial, fungal)*, b, c, d
vse druge vrste okužb (virusne, bakterijske, glivične)* ,b, c, d
all other medicines to treat diabetes, angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure),
vsa druga zdravila za zdravljenje sladkorne bolezni, zaviralci angiotenzinske konvertaze (ACE - angiotensin converting enzyme) (uporabljajo se za zdravljenje določenih bolezenskih stanj srca ali visokega krvnega tlaka),
all other medicines to treat diabetes, angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure),
vsa druga zdravila za zdravljenje sladkorne bolezni, zaviralci angiotenzinske konvertaze (ACE – angiotensin converting encyme) (uporabljajo se za zdravljenje določenih bolezenskih stanj srca ali visokega krvnega tlaka),
all other medicines to treat diabetes, angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure),
vsa druga zdravila za zdravljenje sladkorne bolezni, zaviralci angiotenzinske konvertaze (ACE – angiotensin converting enzyme) (uporabljajo se za zdravljenje določenih bolezenskih stanj srca ali visokega krvnega tlaka),
all other medicines to treat diabetes, angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure),
vsa druga zdravila za zdravljenje sladkorne bolezni, zaviralci angiotenzinske konvertaze (ACE – angiotensin converting enzyme) (uporabljajo se za zdravljenje določenih bolezenskih stanj srca ali visokega krvnega tlaka),,
all other medicines to treat diabetes, angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure),
vsa druga zdravila za zdravljenje sladkorne bolezni, zaviralci angiotenzinske konvertaze (ACE) (uporabljajo se za zdravljenje določenih srčnih bolezni ali visokega krvnega tlaka),
all other medicines to treat diabetes, angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions orhigh blood pressure),
vsa druga zdravila za zdravljenje sladkorne bolezni, zaviralci angiotenzinske konvertaze (ACE – angiotensin converting enzyme) (uporabljajo se za zdravljenje določenih bolezenskih stanj srca ali visokega krvnega tlaka),
All other patients should be observed for at least 20 minutes after administration.
Vse ostale bolnike pa nadzorujte vsaj še 20 minut po infundiranju.
All other side effects:
Preostali možni neželeni učinki:
All p-values adjusted for multiplicity of testing based on pre-defined hierarchy, except BASDAI 50 and ASDAS-CRP
Vse vrednosti p so prilagojene na mnogoterost (multipliciteto) testiranja po vnaprej opredeljenem hierarhičnem redu, razen vrednosti p za BASDAI 50 in ASDAS-CRP.
All p-values are adjusted for multiplicity of testing based on pre-defined hierarchy, except for ACR70, Dactylitis and Enthesitis, which were exploratory endpoints.
Vse vrednosti p so prilagojene na mnogoterost (multipliciteto) testiranja po vnaprej opredeljenem hierarhičnem redu, razen vrednosti p za odziv ACR 70, daktilitis in entezitis, ki sta bila raziskovalna cilja opazovanja.
All p-values are pairwise comparisons of proportions for Humira versus placebo
Vse p-vrednosti so parne primerjave razmerja zdravila Humira proti placebu
All p-values are pairwise comparisons of proportions for Humira versus placebo
Vse vrednosti p so za parne primerjave deležev med zdravilom Humira in placebom.
All p-values are pairwise comparisons of proportions for Trudexa versus placebo
Vse vrednosti p so za parne primerjave deležev med Trudexo in placebom.
All pack sizes may be not marketed.
Na trgu ni vseh navedenih pakiranj.
All pack sizes may not be marketed in all countries.
Na trgu posameznih držav morda ni vseh navedenih velikosti pakiranj.
All pack sizes may not be marketed.
Na trgu morda ni vseh navedenih pakiranj.
All papillomaviruses have a shell or ‘capsid’, which is made up of distinctive proteins called ‘L1 proteins’.
Vsi virusi papiloma imajo plašč ali „kapsido“ iz beljakovin, imenovanih beljakovine L1.
All papillomaviruses have a shell, or ‘capsid’, that is made up of proteins called ‘L1 proteins’.
Vsi papilomavirusi imajo plašč ali kapsido iz beljakovin, imenovanih beljakovine L1.
All parenteral medicinal products should be inspected visually for particulate matter and discoloration prior to administration.
Vsa parenteralna zdravila morate pred uporabo vizualno pregledati in preveriti, ali so v njih delci in ali je raztopina razbarvana.
All partial
Populacija PP
All partial
Vsi parcialni
All participants received 1,000 mg elemental calcium plus 400 to 1,000 IU vitamin D supplementation per day.
1.000 mg elementarnega kalcija in 400 do 1.000 i.e. vitamina D na dan.
All participants received 1,000 to 1,500 mg of elemental calcium plus 800 to 1,200 IU of vitamin D supplementation per day.
Vsi preiskovanci so prejemali dodatke 1.000 do 1.500 mg elementarnega kalcija in 800 do 1.200 i.e. vitamina D na dan.
All patients
69,7
All patients
80,6
All Patients (N = 22)
vsi bolniki (n = 22)
All Patients (N=449) (%)
Vsi bolniki (N = 449) (%)
All patients 50% (42–58)
Vsi bolniki 50% (42–58)
All patients 63% (56–71)
Vsi bolniki 63% (56–71)
All patients 69% (58–79)
Vsi bolniki 69% (58–79)
All patients administered Inflectra are to be observed for at least 1-2 hours post-infusion for acute infusion-related reactions.
Vse bolnike, ki prejmejo zdravilo Inflectra, je treba opazovati najmanj 1 do 2 uri po infuziji zaradi akutnih z infuzijo povezanih reakcij.
All patients administered Remsima are to be observed for at least 1-2 hours post-infusion for acute infusion-related reactions.
Vse bolnike, ki prejmejo zdravilo Remsima, je treba opazovati najmanj 1 do 2 uri po infuziji zaradi akutnih z infuzijo povezanih reakcij.
All patients also received standard antiplatelet medicines.
Vsi bolniki so prejeli tudi običajna antitrombocitna zdravila.
All patients also received supportive care, including pain medicines and treatment for infections and low blood-cell counts.
Vsi bolniki so prejemali podporno oskrbo, ki je vključevala zdravila proti bolečinam in zdravljenje okužb ter zmanjšanega števila krvnih celic.
All patients being treated with eculizumab receive a patient safety card.
bodo vsi bolniki, ki se zdravijo z ekulizumabom, prejeli opozorilno kartico za bolnika;
All patients being treated with Retacrit should receive adequate iron supplementation (e.g.
Vsem bolnikom, ki dobivajo zdravilo Retacrit, je treba ves čas zdravljenja dodajati ustrezen dodatek z železom (npr.
All patients being treated with Silapo should receive adequate iron supplementation (e.g.
Vsem bolnikom, ki dobivajo zdravilo Silapo, je treba ves čas zdravljenja dodajati ustrezen dodatek z železom (npr.
All patients considered to be at increased risk of bleeding should be monitored closely and the dose of Pradaxa lowered at the discretion of the doctor.
Vse bolnike, pri katerih obstaja povečano tveganje za krvavitve, je treba skrbno spremljati in po presoji zdravnika odmerek zdravila Pradaxa tudi zmanjšati.
All patients converted to open-label Kaletra at the 400/100 mg twice daily dose between week 48 and week 72.
Vsi bolniki so med 48. in 72. tednom prešli na odprto uporabo zdravila Kaletra v odmerku 400/100 mg dvakrat na dan.
All patients converted to open-label Kaletra at the 400/100 mg twice-daily dose between week 48 and week 72.
Vsi bolniki so med 48. in 72. tednom prešli na odprto uporabo zdravila Kaletra v odmerku 400/100 mg dvakrat na dan.
All patients converted to open-label lopinavir/ritonavir at the 400/100 mg twice daily dose between week 48 and week 72.
Vsi bolniki so med 48. in 72. tednom prešli na odprto uporabo lopinavirja/ritonavirja v odmerku 400 mg/100 mg dvakrat na dan.
All patients developed antibodies to elosulfase alfa in clinical trials.
V kliničnih preskušanjih so vsi bolniki razvili protitelesa proti elosulfazi alfa.
All patients enrolled in aHUS Study C10-004 had an ADAMTS- 13 level above 5%.
Vsi bolniki, vključeni v študijo aHUS C10-004, so imeli raven ADAMTS-13 nad 5 %.
All patients enrolled in the study had locally advanced or metastatic malignancy that had progressed despite standard therapy.
Vsi bolniki, ki so jih vključili v študijo, so imeli lokalno napredovali ali metastatski rak, ki je napredoval kljub običajnemu zdravljenju.
All patients enrolled were to have had seizures that were not adequately controlled with 1 to 3 concomitant antiepileptic medicinal products, and more than 75% of all patients were taking 2 concurrent antiepileptic medicinal products.
Vsi vključeni bolniki so imeli napade, ki niso bili ustrezno obvladani z 1 do 3 sočasnimi antiepileptiki, in več kot 75 % vseh bolnikov je jemalo  2 antiepileptika hkrati.
All patients experienced a profound myelosuppression.
Pri vseh bolnikih je prišlo do izrazite mielosupresije.
All patients experienced symptoms related to catumaxomab mode of action with a safety profile comparable in nature to the first i.p. treatment cycle.
Vsi bolniki so imeli simptome, povezane z načinom delovanja katumaksomaba, z varnostnim profilom po naravi primerljivim s prvim krogom i.p. zdravljenja.
All patients had 4 to 8 mild to moderate actinic keratosis lesions on the face and/or scalp.
Vsi bolniki so imeli štiri do osem blagih do zmernih lezij aktinične keratoze na obrazu in/ali lasišču.
All patients had a baseline ECOG performance status of 0 or 1.
Vsi bolniki so imeli izhodiščno oceno splošne zmogljivosti po lestvici ECOG 0 ali 1.
All patients had a history of heavy smoking.
Vsi ti bolniki so imeli v pretekli anamnezi močno kajenje.
All patients had been treated with 1 prior VEGF-inhibitor; 65% with sunitinib, 23% with pazopanib, 4% with tivozanib, 3% with bevacizumab, and 2% each with sorafenib or axitinib.
Vsi bolniki so se predhodno zdravili z enim inhibitorjem VEGF; 65 % s sunitinibom, 23 % s pazopanibom, 4 % s tivozanibom, 3 % z bevacizumabom, po 2 % pa s sorafenibom ali z aksitinibom.
All patients had discontinued from prior oral ferrous product (OFP) treatment: more than 60 % of the subjects stopped taking prior OFP due to adverse events.
Vsi bolniki so prenehali jemati predhodna peroralna zdravila z železom (PZŽ): več kot 60 % preiskovancev je predhodne PZŽ prenehalo jemati zaradi neželenih učinkov.
All patients had potential contributing factors for the development of MDS/AML; the majority of cases were in gBRCA mutation carriers and some of the patients had a history of previous cancer or of bone marrow dysplasia.
Vse bolnice so imele dejavnike, ki so lahko pripomogli k pojavu MDS/AML; večina primerov je bila pri nosilkah mutacij gena gBRCA, nekatere bolnice pa so imele v anamnezi predhodnega raka ali displazijo kostnega mozga.
All patients had ≥ 20% reduction in spleen volume after 18 months, and the vast majority (16/18) of patients achieved > 30% reduction in spleen volume.
Po 18 mesecih zdravljenja se je volumen vranice pri vseh bolnikih zmanjšal za ≥ 20 %, velika večina (16/18) bolnikov pa je dosegla > 30 % zmanjšanje volumna vranice.
ALL patients hypersensitive to native E. coli L-asparaginase
Bolniki z ALL, preobčutljivi za nativno L-asparaginazo iz E. coli
All patients in selected chronic hepatitis C studies had a liver biopsy before inclusion, but in certain cases (i.e. patients with genotype 2 and 3), treatment may be possible without histological confirmation.
Pri vseh bolnikih zbranih v študijah kroničnega hepatitisa C so opravili jetrno biopsijo pred vključitvijo v študijo, toda v nekaterih primerih (to je pri bolnikih z genotipoma 2 in 3), je lahko zdravljenje možno brez histološke potrditve.
All patients in the chronic hepatitis C studies had a liver biopsy before inclusion, but in certain cases (i.e. patients with genotype 2 and 3), treatment may be possible without histological confirmation.
Pri vseh bolnikih, vključenih v raziskave kroničnega hepatitisa C, so pred vključitvijo v raziskavo opravili jetrno biopsijo, vendar je v določenih primerih (npr. pri bolnikih z genotipoma 2 in 3), zdravljenje možno
All patients in the study had previously tried other treatments but their disease had either not responded or had come back.
Vsi bolniki v študiji so predhodno preskusili druga zdravljenja, vendar so bili na zdravljenje neodzivni ali pa se je njihova bolezen ponovila.
All patients in the study received supportive care.
Vsi bolniki v študiji so prejemali podporno zdravljenje.
All patients in the study were initially treated with Repatha 420 mg once monthly, except for those receiving apheresis at enrolment who began with Repatha 420 mg once every 2 weeks.
Vsi bolniki v študiji so bili uvodoma zdravljenji z zdravilom Repatha 420 mg enkrat na mesec, razen bolnikov, ki so bili ob vključitvi zdravljeni z aferezo: ti so zdravljenje z zdravilom Repatha začeli s 420 mg enkrat na 2 tedna.
All patients in this treatment arm were limited to 24 weeks of therapy with Victrelis.
Zdravljenje z zdravilom Victrelis je bilo pri vseh bolnikih v tej skupini omejeno na 24 tednov.
All patients included in this study had an ECOG performance status 0 or 1.
Bolniki, ki so bili naključno izbrani za vzdrževalno zdravljenje so morali imeti indeks zmogljivosti po ECOG 0 ali 1.
All patients included in this study had an ECOG performance status 0 or 1.
Vsi vključeni bolniki v tej študiji so imeli ECOG (ECOG – Eastern Cooperative Oncology Group) status učinka 0 ali 1.
All patients included in this study had an ECOG performance status 0 or 1.
Vsi vključeni bolniki v tej študiji so imeli ECOG status učinka 0 ali 1.
All patients includes the 322 patients with undetectable HCV RNA (target not detected) at weeks 4 and 12 and the
Postavka »vsi bolniki« zajema 322 bolnikov z nezaznavno HCV RNK (nezaznaven analit) v 4. in 12. tednu in
All patients initially received Aptivus oral solution.
Vsi bolniki so na začetku prejemali peroralno raztopino Aptivus.
All patients initiated treatment with eltrombopag 50 mg.
Pri vseh bolnikih je bilo zdravljenje z eltrombopagom uvedeno v odmerku 50 mg.